AIMS: To examine AGR2 expression in ovarian epithelial tumours and its potential role as a prognostic biomarker. METHODS: Tissue microarray technology and immunohistochemistry were used to investigate AGR2 expression in ovarian epithelial tumours and in non-neoplastic ovarian epithelium. For the carcinomas, the expression data were correlated with clinicopathological features and disease outcome. RESULTS: AGR2 was expressed in all benign, borderline and malignant mucinous tumours and in a high proportion of endometrioid carcinomas (89%). AGR2 was frequently expressed in benign and borderline serous tumours (76% and 95%, respectively), but less commonly expressed in serous carcinomas (19%, p < 0.001). AGR2 expression in ovarian carcinomas was inversely correlated with p53 and p16 expression (p = 0.002 and p < 0.001, respectively), and independent of CA125 expression. AGR2 expression was more common in carcinomas which presented with early-stage compared with late-stage disease (p = 0.009) and AGR2 was expressed in carcinomas with better outcome (22% relapse rate of AGR2 positive cancers compared with 74% relapse rate for AGR2 negative cancers, p = 0.001). CONCLUSION: Our findings indicate that AGR2 expression is associated with mucinous carcinomas and their precursor lesions and endometrioid cancers. Additionally, AGR2 may be an important prognostic biomarker of ovarian cancer.
AIMS: To examine AGR2 expression in ovarian epithelial tumours and its potential role as a prognostic biomarker. METHODS: Tissue microarray technology and immunohistochemistry were used to investigate AGR2 expression in ovarian epithelial tumours and in non-neoplastic ovarian epithelium. For the carcinomas, the expression data were correlated with clinicopathological features and disease outcome. RESULTS:AGR2 was expressed in all benign, borderline and malignant mucinous tumours and in a high proportion of endometrioid carcinomas (89%). AGR2 was frequently expressed in benign and borderline serous tumours (76% and 95%, respectively), but less commonly expressed in serous carcinomas (19%, p < 0.001). AGR2 expression in ovarian carcinomas was inversely correlated with p53 and p16 expression (p = 0.002 and p < 0.001, respectively), and independent of CA125 expression. AGR2 expression was more common in carcinomas which presented with early-stage compared with late-stage disease (p = 0.009) and AGR2 was expressed in carcinomas with better outcome (22% relapse rate of AGR2 positive cancers compared with 74% relapse rate for AGR2 negative cancers, p = 0.001). CONCLUSION: Our findings indicate that AGR2 expression is associated with mucinous carcinomas and their precursor lesions and endometrioid cancers. Additionally, AGR2 may be an important prognostic biomarker of ovarian cancer.
Authors: H Guo; Q Zhu; X Yu; S B Merugu; H B Mangukiya; N Smith; Z Li; B Zhang; H Negi; R Rong; K Cheng; Z Wu; D Li Journal: Oncogene Date: 2017-05-08 Impact factor: 9.867
Authors: Mariana Rezende Alves; Natalia Cruz E Melo; Mateus Camargo Barros-Filho; Nayra Soares do Amaral; Felipe Ilelis de Barros Silva; Glauco Baiocchi Neto; Fernando Augusto Soares; Louise de Brot Andrade; Rafael Malagoli Rocha Journal: Cancer Med Date: 2018-05-29 Impact factor: 4.452
Authors: Brittney S Harrington; Yaowu He; Claire M Davies; Sarah J Wallace; Mark N Adams; Elizabeth A Beaven; Deborah K Roche; Catherine Kennedy; Naven P Chetty; Alexander J Crandon; Christopher Flatley; Niara B Oliveira; Catherine M Shannon; Anna deFazio; Anna V Tinker; C Blake Gilks; Brian Gabrielli; Donal J Brennan; Jermaine I Coward; Jane E Armes; Lewis C Perrin; John D Hooper Journal: Br J Cancer Date: 2016-02-04 Impact factor: 7.640